> ## Content Index
> Fetch the complete content index at: https://www.biostockinfo.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# BIOTECH CATALYST AI SCANNER — September WK3
- URL: https://www.biostockinfo.com/biotech-catalyst-ai-scanner-september-wk3/
- Published: 2026-09-13T17:50:23.000Z
- Updated: 2026-09-13T18:17:27.000Z
- Author: Alex
- Tags: AI, Biotech Catalysts, Biotech Investing, Catalyst, Catalyst Calendar, Catalyst Scanner, Machine Learning, SEC, PDUFA

The weekly scanner is back. I paused publication of catalyst scanner since end of August to rebuild the system. This is the first edition powered by BioStockInfo’s own catalyst calendar, which I’ve developed to make upcoming biotech events easier to track and check, and available for free for everyone. 

The new process includes two layers of fact-checking: checks within the calendar, followed by a separate review of the catalysts selected for the newsletter. Even with that work, the system is still early. Errors and omissions remain possible, and keeping it accurate will require ongoing checking and updates.

Clicking “open company calendar” will take you to the comprehensive ticker site from the new calendar, providing access to the latest news and SEC filings, as well as financial filings. If you notice any errors in the dates, missing catalysts, or inconsistencies with the source, please let me know. Your feedback is invaluable in enhancing the data for everyone  

BIOSTOCKINFO / CATALYST SCANNER

Scan date 2026-09-13 · 10 featured · 10 watchlist

## The tape

XBI closed at 156.20 on September 11, down 4.7% over one week and 2.0% over one month, while gaining 16.8% over three months and 28.5% year to date, sitting 7.9% below its 52-week high of 169.55\. By comparison, SPY closed at 764.29, declining 0.8% over one week and 1.1% over one month, while rising 3.0% over three months and 11.9% year to date, sitting 1.8% below its 52-week high of 777.88\. The week's sharp underperformance in biotech reflects a sector-specific pullback rather than a broad market decline.

Market breadth softened as 33% of the 5,930 tracked US small and mid caps closed above their 20-day moving average on September 11\. A breadth reading at one-third of tracked equities indicates an unforgiving tape for speculative names ahead of clinical catalysts.

The US 10-year Treasury yield stood at 4.97% on September 11, climbing 4.0% over one week, up 10.9% over three months, and sitting directly at its 52-week high of 4.97%.

## This week at a glance

| TICKER            | CATALYST                                           | DATE                   | RANK |
| ----------------- | -------------------------------------------------- | ---------------------- | ---- |
| [**IRD**](#IRD)   | PDUFA, Phentolamine Ophthalmic Solution 0.75% (PS) | Oct 17, 2026           | 83   |
| [**AKBA**](#AKBA) | Topline Data, Vafseo (vadadustat)                  | in Q4 2026             | 80   |
| [**IONS**](#IONS) | PDUFA, bepirovirsen                                | Oct 26, 2026           | 80   |
| [**EIKN**](#EIKN) | Conference Presentation, EIK1003                   | Oct 23, 2026           | 78   |
| [**RAPP**](#RAPP) | Topline Data, RAP-219                              | October 2026           | 77   |
| [**PHAT**](#PHAT) | Topline Data, VOQUEZNA (vonoprazan)                | fourth quarter of 2026 | 77   |
| [**CLDX**](#CLDX) | Topline Data, barzolvolimab                        | September/October 2026 | 77   |
| [**BDTX**](#BDTX) | Interim Data, silevertinib                         | fourth quarter of 2026 | 76   |
| [**ARVN**](#ARVN) | Conference Presentation, ARV-102                   | Oct 4–Oct 8, 2026      | 76   |
| [**MRK**](#MRK)   | PDUFA, WELIREG                                     | Oct 4, 2026            | 75   |

Top 10 names by scanner score, highest first. Rank is the scanner’s score out of 100.

## Featured

### IRD — Opus Genetics, Inc.

CATALYST**Oct 17, 2026**Regulatory

RANK**83**

PRICE**$6.04**+62% 20d

CAP**$502M**(83M sh)

CASH**$81M**\~24 mo

FTD SPA

**The FDA has set an sNDA PDUFA target action date of October 17, 2026 for Phentolamine Ophthalmic Solution 0.75% in presbyopia. FTD, SPA.** The decision determines whether partner Viatris can commercialize the eye drop as a non-ciliary treatment for age-related near-vision loss.

**Company.** Opus Genetics develops gene therapies for inherited retinal diseases alongside late-stage ophthalmic assets. The pipeline includes clinical candidate OPGx-BEST1\. It generates no product revenue, relying on cash and recent financing proceeds to fund multiple clinical programs.

**Science & competition.** Phentolamine ophthalmic solution blocks alpha-adrenergic receptors to relax the iris dilator muscle and constrict the pupil without engaging ciliary muscles. Rivals include Vuity (AbbVie / Allergan, FDA-approved (2021)) and Qlosi (Orasis Pharmaceuticals, FDA-approved (2023)). Standard of care is non-invasive optical correction using reading glasses, bifocals, or contact lenses.

Competition sources

Sources: [presbyopiaphysician.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHRuMSGkp32TpwkZxKegerPub7i-i%5Fj3UgqbjqHP4h2OUf3oyNaGzTJwM9MjariE1a5OsyF7Lf5DSMCZiU-45f0kLwjkCy7MUg45mqoA08xwpUuWyGkUWDUM1BK4QfB2EebwufX4n9TUIwefPx-1xv2zxxNER0L8DeFsufmueot0OTYkj9Lf3Nonpi9UkMp?ref=biostockinfo.com) · [ophthalmologytimes.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE34Aq5TaeIotI0-YCKIX6nmeDNoYp8WZhJAsxgfk9uIp5y5HfrImtr0Pxk4xn8d1a1JTWMfOpXD-NOfa7YI-MxYiiEDYB56s7%5FOiLpCN1r9lC--BoRzWi8HGHBMs1OZRCDkFAxmwLn4gDocjb-dfTfOArWDFLBR-1PfLvSmBeVkc0CtCy1n4%5Fnm8gP18gsV3QY%5Fry1MqR-tCaSpTyD?ref=biostockinfo.com) · [reviewofophthalmology.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG41TK7Fuw0nxmo3kf2f4uuNQ8qC-rMEYbq3PAjzB0mN9p95j4Q-0tB1iqWtXtdxt%5FV7E1i23PFJz%5FRJyAxF7eMCYco5Flne4nlyxgaBoNY%5Fj18y0Bt7ocg7MA3OcLM1JggZKQvFtVVNxT6HsDJ92k2lapMHaov980N4ZzyhTwumYdFGCX7%5FIV%5F2vPi1u2wy3Tll5Dq2vx26NykR0UyYT9f?ref=biostockinfo.com) · [drugs.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG5v-3aN4KymT2LgffYvei2bhr9ps2AN9EphsVwY3R-r5SvNB-tUEWqSKrlZ%5FoEOq5UKrNgS%5FZLdrdMeRtCJsIkSFgHAhWb%5F84VGbY-p5k0Cl-Ao1eIKOxwOX-4vN8Rx92noDXQUN05VEDY?ref=biostockinfo.com) · [ophthalmologymanagement.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEN14CGgtnGu%5FUwB-coSfmmd4RHpCgNCu8BLKZe6ocVdU7P%5F0Q2PE1zhzUKgRVQSUGKmWKtYeKWRmvGteJbi3tghmsb%5FHyPUNFEBAwkabxI124ytmK8Dv3R%5FbyxW-viZ8hZYzg2VMNx35OL1LWxC-LXWJrah%5FEDe3r5NubiBpuwxZipLckWGKXZUJBke42K29M=?ref=biostockinfo.com) · [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHYYjmREheH9yX3jPhkNApkDYBJQF-KaENRbePJGWunjlKuyVu%5Fh7rEu5AnUYtQFVZ2giDWbx4IPu6ZsafdS%5F0RgikVs0m15WMaJhOXAI3qoAINpX31kTPAP5CUHCnZ7kdrVsQa6s3ZsBAW9a4P?ref=biostockinfo.com) · [ophthalmologytimes.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGM-gu0i5zDEYJEykoYm--BkNYjwZ82h22h9uMakpmusfINWZRTqKG5HXANmGGL2MoLpIOlr2inuWNdkmJNU18nxfZBVVVdTR4uS-a-AoO4URJ67a4SxHapoTNxNUV%5FqWZ0ahy9MOArUbW15t8lePuRotCbKwAGNjPtbZgtyvkm8mzh5j-qn3adi9fiBT3ybMN%5Fi9NDpG1pqM1kwYagEY0zbrnh?ref=biostockinfo.com) · [evolutionaryeyecare.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHYuOuakT9Ocq50SK25KuPSI70xfAWCLQwWoMw0Pd2sGEmokZPrQZRyZ8n7fS5PTLFN81iNkjq2D3Pp-k1XeqFqKqRbaFUR6T1qMGM165pV5S-AgtbJDS5VWuPaAuPUlT2kO-LK5HLCj8ekauKt0z3yBUAgZC2JuJ3utStKpmkNw0faFqWC2uZcIXbki44OQq8PDxv-%5Fw==?ref=biostockinfo.com)

**Why it could work.** Phentolamine constricts pupils without stimulating the ciliary muscle, avoiding the headaches, brow ache, and myopic shifts common to cholinergic agents while preserving distance visual acuity.

**Why it could fail.** Commercial adoption for presbyopia drops has historically lagged due to poor durability; any regulatory rejection or restrictive labeling would concentrate value entirely in earlier-stage gene therapies.

**Recent development.** On September 9, [Opus reported](https://ir.opusgtx.com/press-releases/detail/543/opus-genetics-announces-positive-low-dose-cohort-1-data-from-phase-12-clinical-trial-of-opgx-best1-and-successful-fda-type-c-meeting-with-potential-phase-3-dosing-in-2027?ref=biostockinfo.com) positive early BEST1 gene-therapy data, adding a clinical update from its retinal-disease pipeline. This concerns a separate programme from the phentolamine application featured here.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=IRD&ref=biostockinfo.com)

### AKBA — Akebia Therapeutics

CATALYST**in Q4 2026**Data readout

RANK**80**

PRICE**$0.95**+9% 20d

CAP**$264M**(277M sh)

CASH**$156M**no net burn

Filing warning

**Akebia expects topline data from the Phase 3b VOCAL trial evaluating three-times-weekly Vafseo versus erythropoiesis-stimulating agents in dialysis patients in Q4 2026 (company's words; quarter-level precision).** The readout determines whether hemodialysis clinic dosing delivers non-inferior hemoglobin control without elevating cardiovascular risks.

**Company.** Akebia is a commercial biopharmaceutical company marketing Vafseo for chronic kidney disease anemia. Its pipeline includes ebribafusp for glomerular diseases and early-stage candidate AKB-9090\. Vafseo generates sequential revenue supported by cash and ATM financing proceeds.

**Science & competition.** Vafseo is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that mimics the body's response to low oxygen to stimulate red blood cell production. Rivals include Jesduvroq (GSK, FDA-approved (2023)) and Epogen (Amgen / Janssen / Pfizer, FDA-approved). Standard of care is injectable erythropoiesis-stimulating agents administered intravenously during hemodialysis alongside supplemental intravenous iron.

Competition sources

Sources: [fda.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH8WDIriLw6Ki0M0%5F4-oxzy6516DkeRizT8GhYbVAjE1gX4Af2R40KAb1rAOu35v5k0jzevNg87fvyipndArcczrjJ2xJSsbSwFa8FWi4%5FSkFywhgO%5Fj2qDosBRzvSq8UbME0Mj8HYa5wjND-JstBFFYfwWo0FUOucRkO2hPbYaNqP7tW4HSocgceFOjA==?ref=biostockinfo.com) · [csl.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFcVRVNsSVNgwZM3fFMPlIXL5kjE0N4c2q5LojHUmqGfAgHs5XYeHMZ52rCNjNTSm6Ma%5FPGN3aVLR0j71%5F5Nrc7OkbLlMKaX3pghxkSiB86kvdPW8lqRbFwIXL0GRAjy8Bun7ARDlYAhJTluO9gTZ9muvGEIa3KWzVxVtnOmHFk5bC6bqmeArcF7LIdC2jYSpTFC7rLo7pD-j5-Ft0Y3n1GM%5FzRyFVH7VrrKfTK1noKZLTMam4pHwL1kn0fJa6E1V7A1jYJi7WyerPZdvzhmoRgVwX2UfzSCKex0ENd4rEr?ref=biostockinfo.com) · [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFsiaTXD1TON-wPUPqMepIY84AbtNQuO2VMHrxnFvrrX--ShFBSIZcXkoZKo-wvr0k-LLlUF322u7r27Ic2Fiz1-VpLvXBywV5iBlKfHww%5FKqTXxjjojmt-KwlX%5FXF-cyhISDIX?ref=biostockinfo.com) · [pharmacytimes.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGlD6mCecMW8ZMXE%5F3kf1CGLg34jLOVOzzyFK-ex7kWiaqB3Tf%5F3rCbeVs2cJFDcWSaSY8ZT5cXLExX7Oc%5FsNNgo4C41IoZJ7gusX442VJZMK1A1aMP7Tl%5FXhrZcHTNQoDN4MsAlXsr4b5OGH6ogx7KRku-E3bHaCOag6mUZmuxwqwJlTVuT2xtUBSVhCmotBOsALR9Yw5bGIvCoZCMDYu%5F5X%5FIoOjKeTu3J11tVl30VMVkPd-J4Axq?ref=biostockinfo.com) · [gsk.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFuki6Df73V2IF%5FPcQI9I0V4BJkcjBn9fmdtgJuW1qNfuf7nUqwEHZUKR3r5AtpDwt0KMMSKu-iraPduTF3I9jbndBT1Czf%5FFBa6OvnjVMiy4xMe3kyItGUXxld05dQnUt-DO0BbhLdtOs9xpCv6sUAlsSg9kFMgeV21qqPCdwUdUmnZJAlfohL%5FhwnhWJKJaKeQ-f9QcPcVrCMu6vryN0U%5FNqdQy%5F8pXuCsBd5ShK4lGOpTfj38pTm26daswiJtKRDtWJDj4GNsf8C4w22Q2B%5F?ref=biostockinfo.com) · [prnewswire.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGMdiC1n%5FRdLfq9lHxTdn1RETj7g5-8QNNUiHRvDmp9RhbmlY9fDJiFw8%5FgpbDCm8YQh0Uts338oXBrGzEEZDHxLx%5FcZFHT-4IH-OZiVHqy7qypZkumTEiaTJTBzSUosPlfgxBy-UQHHJ%5F%5FuDkQRpIjzodMsRP2krYUaCUNy4rYLuNVFENPfdiTZUyZ5RGBT2My4V1QRzj4XsIeAFI6KUEXM1lfBkM17imfQ3Uv9bJWc8v8XVjOwxqxU2FFb20c2-5Ne9NhlfQPW5SQieRJVyn6C8wDuHZySgE=?ref=biostockinfo.com) · [clinicaltrials.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF3ttihDOzBL05c-4j1FlHCYvckYLY4LEt-x7Bf7qlocBwatHkuo9I9vuWGcTKw2zpa3PlAjSEaBo0y9IJHNX14xDzd8ZgKgUXTYfoMRPJ0OCAx-ZR9LlLuLVKan2AJLljdTwu6SJEn?ref=biostockinfo.com) · [oup.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHBAW2PFtLzPY5h1o5CTjSL12IyDfJNlGkMZYa%5FOrz%5FzocTmsCfae441zBkqBusOegYrzhhY0gdtsOlJULWmo%5FJ8K0sDMaZre7PK0Oyq2tFXVFw6Eu8v-4mihq5e72mUPZVuVONLniAA67OG2RXzzwNIA==?ref=biostockinfo.com)

**Why it could work.** Prior Phase 4 VOICE interim data demonstrated a 10% reduction in all-cause hospitalizations over standard ESAs, giving dialysis clinics an economic incentive to adopt three-times-weekly oral dosing.

**Why it could fail.** Large dialysis providers have entrenched purchasing contracts for injectable ESAs; any safety imbalance or failure to demonstrate hospitalization benefits in VOCAL would stall commercial conversion.

**Filing flag.** Net loss was $8.9 million in the second quarter of 2026 compared to net income of $0.2 million in the second quarter of 2025, driven by lower revenues and higher expenses, including a $1.9 million restructuring expense related to a commercial organization reorganization.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=AKBA&ref=biostockinfo.com)

### IONS — Ionis Pharmaceuticals

CATALYST**Oct 26, 2026**Regulatory

RANK**80**

PRICE**$54.20**\-3% 20d

CAP**$9.0B**(166M sh)

CASH**$2.0B**\~48 mo

BTD FTD Priority Review

**The FDA has granted Priority Review for bepirovirsen in chronic hepatitis B with a PDUFA action date of October 26, 2026\. BTD, FTD, Priority Review.** The regulatory decision decides whether Ionis and partner GSK secure approval for a finite-duration functional cure option.

**Company.** Ionis discovers and commercializes RNA-targeted medicines across neurology, cardiometabolic disease, and rare conditions, including recently approved ZANVASTRO. It generates collaboration revenues and milestone payments from partners, backed by a multi-billion-dollar balance sheet aiming for 2028 breakeven.

**Science & competition.** Bepirovirsen is an antisense oligonucleotide that binds hepatitis B viral messenger RNA to trigger degradation and clear surface antigen. Rivals include Interferon alfa-2b (Schering-Plough (Merck), FDA-approved (1991)) and Lamivudine (GlaxoSmithKline, FDA-approved (1998)). Standard of care is lifelong oral therapy with high-barrier nucleos(t)ide analogues like entecavir or tenofovir.

Competition sources

Sources: [umn.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGcnWJ7sgxQVF8NOs3D0RnOr6Qi8SBGzIs0dwRrLWENAXVnQ%5FbSLPHR46HZqEm8aAsLC%5F9GCWuZABAHRSEL6OgXAMC0cJIdHcN8esjUMVDCUCzlQ5rVx7OynZPz2Q1gI7nl33DVuPEy9mZW5YybvAfDx7AfLX5qbr4k9sRalJdbDV1u2i%5FD%5FElrmr92DR1wa5RLebYSaB5JHpNot3ANl6L82gg2FM%5Fz2bJfclz9rQc=?ref=biostockinfo.com) · [gastroenterologyandhepatology.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEWAaq9Jf-woMqAGXwzGLYUchiepNhVKf3b1s-ZR7iPdTo4MNKpWXlFrAwKJAPpQhYmFh5JNQVVS5b%5F91Tx5-86a2DJR9dmTwyWr5ELsOIo9O20sZusv6s3Y-NDUs%5FVYzWdNccwUfWZZsYXfwZGfWgrvBLttvTxXJA8%5F8thfd77fc-J84W3ZAHh3n8MzB0HWdjBRk1R4nGMSvUPIK4KH3zNXoMLMkDsTd-eLe%5FxO73taSol5Kd%5FY0W3Vr8TKhm-?ref=biostockinfo.com) · [biochempeg.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFddZjwfOvP7JXEkyGUpP173iAp160--BtCZea80Q93Q0JPwRyLdM%5F7T2muNbJgjKupn0O4vpV3q22XblJpBJgywLFvorT6vGAdCYfsrID1-rW0CibxOrunrjFnz1C2rXR5Tblstac4?ref=biostockinfo.com) · [ionis.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHhbPBuQoIpdAiMHz47nSMD48JbFVnrmWrGIKzDYVGf1SFqo0JB8wPyhbXzBvZNdr4tIpNZKN5-vk1e1y5J9MDKuDLreaH2HfCKIV7tUxDLhuVNFKmR0q0ePjbyDFxQ0hDDMYVdWL%5FHyXm%5FWIdnw%5F%5Fo7wlkQRfDrSQ8jUv6wFyvcv%5FR9PwycxuaG-XKX8Mn5FoPklVlCRGGTM85c8MoX5pw7I721mzNaxSoAC-jOJGCKcMW?ref=biostockinfo.com) · [ajmc.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEEi6sebEBpQCJVAI23M3thoPRgjXb8cV8zCTAtxRXfSZYnr8mzBO%5FoklL0hL-ysfpEfEQlfHen5Pa4CgbFX-NkBVJcmwrTk3ugJZJ%5FQw8IP3B0eifyaQQxgDdqMU%5Fb-5qJR6xmc1WoW0uNt5S4IhhuMwvC9BA87H2mqrd%5Fa9s-umL6B50khkXmbyaR31w=?ref=biostockinfo.com) · [rxdatalab.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGAKEeOVEtj1cEXxcwdZzMi0vjOoPLj140BlElKafxrip4o-kErCwxpbmq2X0TZYqrdQKCucpQKVpJvfTvEt7nsWORMpFY42kOr6TzckLULAcJ7xSwhHki0us30IoJW%5FPnVlC9JShDKusmWrAuvxDu276v6t0IOuXnSrTrnNDHVcnc0XYJmdYHh15zHf0vcqA==?ref=biostockinfo.com) · [contagionlive.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEhnmvLNtZypr6y0Vv%5FCjfw2TwdDGHB6aCoIGj3XBSoqOQyR-CyFAv5DC0MkPl%5FhwXyUs-4JHCkewOpMfDk4l7nFHwMJodO574WlEaQcW-JliqxxHHZoaNNnU1PlefAi1qOWcMxOd2iqEdwC5aNNISYlL5ndLKx1A0ssSSZhs8yV2ofXKXBhGCt1rpZTA8vdaGNjCL1ICbu-5VgA-REinsLfKzEIrgG3Q==?ref=biostockinfo.com) · [patsnap.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFWHTVaL6ZKbDuueAtp8oUfEZrrE8EDFvNb4Iit4q358zimHKdjtmqygM0yvBISh4wAct-Cli2iTDnsBvnOjcdEZLGUy8FwSLPwimoc2xEe7N9EOqlp-xMXaaayzAB%5FFhqnTNf3Iy9KV8FMgY2Jc1TjjoJ9RCpSq-aX2A50?ref=biostockinfo.com)

**Why it could work.** Current generic antivirals achieve a functional cure in fewer than 2% of patients; bepirovirsen's targeted antisense degradation clears surface antigen to allow durable off-treatment immune control.

**Why it could fail.** Transient antiviral clearance can trigger post-treatment hepatitis flares, and safety scrutiny over hepatic inflammation or off-treatment viral rebound could lead to rejection or narrow labeling.

**Recent development.** On September 4, [Novartis reported](https://www.novartis.com/news/media-releases/novartis-announces-lpahorizon-phase-iii-topline-results-pelacarsen-patients-elevated-lpa-and-established-cardiovascular-disease-cvd?ref=biostockinfo.com) that pelacarsen missed its Phase 3 cardiovascular endpoint. The setback concerns Ionis’s separate Novartis-partnered programme; it does not establish the outcome of GSK’s bepirovirsen application.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=IONS&ref=biostockinfo.com)

### EIKN — Eikon Therapeutics

CATALYST**Oct 23, 2026**Conference

RANK**78**

PRICE**$8.94**\-13% 20d

CAP**$484M**(54M sh)

CASH**$477M**\~22 mo

**Eikon will present clinical data from its ongoing Phase 1/2 trial of EIK1003 in advanced solid tumors on Friday, October 23, 2026 at the ESMO Congress in Madrid.** The presentation decides whether this oral combination agent demonstrates acceptable safety and antitumor responses in heavily pretreated solid tumors.

**Company.** Eikon Therapeutics is a clinical-stage oncology biotech developing small molecules including EIK1001, EIK1003, EIK1004, and EIK1005 for solid tumors. It holds no marketed products, funding broad development through net proceeds from its February 2026 initial public offering.

**Science & competition.** EIK1003 is an oral selective small-molecule oncology agent evaluated as monotherapy and combined with abiraterone or paclitaxel and platinum chemotherapy. Rivals include Olaparib (AstraZeneca / Merck, FDA-approved) and Niraparib (GSK / Johnson & Johnson, FDA-approved). Standard of care is platinum-based chemotherapy, immunotherapy, or first-generation PARP inhibitors as monotherapy or combined with ARPIs.

Competition sources

Sources: [eikontx.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH-N91jCtll-KxBkWKVvtd0hf-a%5FIcpKa86YHYjPB7PDqxDUsXu4bTERVygVBTM%5FJ8e%5FoNspknSbM42U2AYS%5FBwbbkvpBhVDG6hOv%5F9DeA91B-n9FtG%5Fk7yNxsfpa2gBWWakZ%5F0hg9PG4rE1gMCZfI%5FNUg86aIIaaWXL13va9ni7TrXaJ0leCpV8gQey5aEMgjmLOEK6axbg1wwcdjKBfbUJYQxMJAvYpOpvoaAdBWJC8OLP2c8?ref=biostockinfo.com) · [eikontx.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0opLj8ZnB1Ygf9v4-f2%5FSGsQmWKwIYElDTLiErnVoia-nt4BpUAh-H5UEBdVBTAqkDEKV%5F4bJYWl7PG%5FQE7dZ1Z5SJmRQFWyaxgKATZmKcty4nZHAIp9Qq3Ua5nOJkev%5F6XpKoZsVcDu17bJv3U6JSYiBr%5FKBPQKS1BIWUo5lDhxiw1vocuHgzvi4uY18bpGZRAtnRXxIaQIgMlzeyTg=?ref=biostockinfo.com) · [sec.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGOtB8T9B%5FJJFPMXHzyOgJ7hoXoWZA2qK5cdB3yORpkypb3w0GuQLSw3vWqzWqVzQ38bVtYFeRFNUJHXlQNZTTnQSIzz4x4A5dnTZChoApM8kP-tY5GFaHMNzH1Nbg8C8TkIsKkWKCIle3MSDQrhfV0wU0hc%5FwC5Yi-jlZNfXjv9K-JlmyvSR2bpXeuEw==?ref=biostockinfo.com) · [clinicaltrials.eu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFOsfzepSwXGSYOB%5FtkbT4hMcWPvf4n%5FjhcGC3nh48ogHGxgjyaRm2r-bP12JYcdXTsQfwdKLdc3d1J3TyQLoMr1Xsw%5FaLbPiH9kll47hUsRAj%5FkWjxYxcufiWBHN1RSVd8?ref=biostockinfo.com) · [impacttherapeutics.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFWrJM%5FecWEOcfkr74c6FheznKb7nePiBukTNKQcZifM9YbIdbt3wfmgexuW8EO-Gh4WqO2i9g92mgFEBs2%5FAuT3Sa7f36IlBDK7q3gAILkYlE5MPwi-3WhbfLP%5FP7cjOzkGW4B4fSSLw==?ref=biostockinfo.com) · [biotechprimer.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH9Kd7wAHB%5FswuxIX1LFiVbRXcTbJwHQQCjwtmdgSCap0Guul0o2aMrqT8d2-LelaF2UciUU8cYovacGuZtnTqWSfNGputv1VYdf2PyPDhBWjksLtxopeaz92W8UKsTFLUj7FZAsrs=?ref=biostockinfo.com) · [delveinsight.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG3cHtLHXCWhGkKXTbh3HnDNSclcPuaIjQDhPXT4vrpqX7DNGhqjzImWdBcRfIOr8kRlWXPnw9vHM33M%5FCwl1hDmdItwnzOVcLo1QC8260SaT%5F9Si8c6Ql1hMfz28ru7ZLKvXXa%5FsUF0FwgjL5SUzXoSDefP3DIpmlTEOo2KzV3QxUoi6Gd?ref=biostockinfo.com) · [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHU01-1hcrNu4dCi6AEN510rsrmOWX75RsBbvvBYTu-OAU8-pDqoQOm-z0X20NWQACXdoi6ZkoJUF2gkswp%5FCYoVpAfCOL4hySBvtpK1CdKunSvJxj-wV3vah2cF06wMdyLHkeAdpgD2UVXXgU=?ref=biostockinfo.com)

**Why it could work.** Prior Phase 2 data for lead candidate EIK1001 demonstrated a 63.1% objective response rate in NSCLC, showing platform validation for combinations targeting multi-pathway tumor resistance.

**Why it could fail.** Combining experimental targeted therapies with cytotoxic chemotherapy or hormonal agents frequently compounds treatment-limiting toxicities such as myelosuppression, forcing dose reductions that negate efficacy.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=EIKN&ref=biostockinfo.com)

### RAPP — Rapport Therapeutics

CATALYST**October 2026**Data readout

RANK**77**

PRICE**$43.62**\-8% 20d

CAP**$2.1B**(48M sh)

CASH**$416M**\~52 mo

**Rapport expects topline results from the Phase 2 trial of RAP-219 in bipolar mania in October 2026 (company's words; month-level precision).** The trial outcome decides whether selective AMPA receptor modulation can treat acute psychiatric mania outside of epilepsy.

**Company.** Rapport is a clinical-stage biotechnology company developing precision small molecules for central nervous system disorders. Its lead molecule RAP-219 is also advancing in Phase 3 focal onset seizures. The company generates no commercial product revenue, operating on cash reserves.

**Science & competition.** RAP-219 is an oral negative allosteric modulator targeted selectively to TARPgamma8-associated AMPA receptors to dampen localized excitatory brain signaling. Rivals include Lithium (GlaxoSmithKline / Generic, Approved (1970)) and Divalproex sodium / Valproate (AbbVie, Approved (1995)). Standard of care is first-line monotherapy with lithium, divalproex, or second-generation atypical antipsychotics.

Competition sources

Sources: [psychiatrictimes.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEwe4QVPmeyC7I41sTBncuXNGCbe3JWkOd8PkI3TTTvWXP0XdskviUAE73meczrXRazA8LcI2lkja2aw2H5ve0waHz-TcX1kd26lGliKMsnGLNTA3lg-6ROo1zYKe1hGHWL4L-6ofTOYJxbunvIG5puyALp0gxQ4Jp08KH7Cv0F9uoIxXTnj1Ps1yobvCrKaIyJHQf1UgSqcHbtFRzsyQY22eZGSH7P?ref=biostockinfo.com) · [psychiatrictimes.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE2M0L-rNte-XGGC6KhJ%5Fgt36MHgk6xSk33sqZ4%5Fyfxdgm8I3ZpUgqIO2zLeIuEZQWs66pMaXF4vhli7bqr1dFxItxG0kdeUu70bNsuOH4BiHge4DV8FM-EknOQjl1o9CzK0axE9CaXmHDM2B5ogDtUmWMkXI4bS%5FrQ3ZEk5Vo7cvYgPgyWLQR5I%5FKyPJWzBplmD%5FzCsZ8ZFaZ%5FjrLns8H81HQnKPN-?ref=biostockinfo.com) · [clinicaltrials.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG6S7UlSOmsM41rxhTCNc5gs9LdPcplRPsgFrLznCf5lLrbQP48ZpsRKKShy3ZSBq9dcSCVa1gw5x3PwRvmF0N53Wuc5YCjgz4pBRywjbgB3W%5FHc10%5Fx5lclcdFlmmBYos-Kj4v43i1?ref=biostockinfo.com) · [psychiatrictimes.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGFw7UC8WLzGNfR5vtGJ1y63LJE6RMyGLqrrYpTeeNZoAyk8XDQSl9VZw6aVM-cm57aMZqZj0Bxu4gwq4F6v-6xcO1QfqpnjiJMVM1f99CNl0cc1N8xHOBE28fSMkbHxneXOh-WksNeydN6%5FseCAQJTbT3og6TB70OQ0znww3YK2Gw79wp3QBGO?ref=biostockinfo.com) · [ajmc.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEXBFjIuUc5djVFErCZ07wwcwUW0Bt6pF7eedWt9L-99TA3APgPsjB4nxNB70oFa%5F1DNrp7woqSHVMR7RkjFKZ95VBJhfhyLFVnXLIdiJt27uWLkR1s-2sDQh7hpZsYUC8Jerc-VEKzStvFJ3d02kVau1jHNZpPZtqf1NrutPFr1TpbrzblUmIJn5mrR1NDVpY=?ref=biostockinfo.com) · [psychopharmacologyinstitute.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHdyNUkmHKHtYQzKetaBiZx077moA9gp2ldNUedK%5FwKgUybPzVt0oIDtXJ557o-lyN2cRJogbV4ie1LaY9ZnEkKcBOCOIflBv7fWAYL%5FUugda9QTvD-9h8maw%5FlmCFsmSIPMxGXwhRW%5FHRdws7YQmPlcHlXDjXKjnH6Z5ji--j2TSbNbrGUWzw8fE%5F%5FnIQz2eFv5n4qSp5I8OptnRxLkfxKZU05Xfv5e5PUUy9CAmrRxV-7EwiKNC7j5LDv5d%5FhdewgFDjuhF%5FfU%5FqS2r4fsmW8LJM7nq9pDJCl%5FwNHYQ==?ref=biostockinfo.com) · [jnj.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHgh5QPZe-MgbJfGYfhJf553YCe2lJ9C5PDF58cR18Hr47xnUAr7-4SaF0O3awo3baTHF1ZFZY9nsiDdW4bFfEdAOMD6x23ZhofISRWb4AE25CQ91sNyvpH-PokKD1YXxF5xq92ghbqCf4D47e5MG2YDZn5nCq-OWRfLO7J1GnNHsQwd2pHGqolnOg9toJKIl4jLzLeKHcm1gFXq6XhBT4uD50G3e3FXWrdbRcC%5FSSQ7Vc-pepjtCmGJY8Rsx%5FSxURslV6wrGRHsVsbNK9f5mdO9jWA1pPN2ITXpVoYU0PvB0Te8ssLpb2X?ref=biostockinfo.com) · [clinicaltrials.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGyoUZTSmBxdNcp31jarwBoGo-gZuL3YhKqszDLwMMWwyf72-QvLd5L5Z68lM-3ct8Ro57tY1dvlKLAKlbY0%5FLqAprS90PRGFMklewhPNAlcRLXnOBksaAySqkeWRh3GMIiFBMqKtu2?ref=biostockinfo.com)

**Why it could work.** Phase 2a epilepsy trials demonstrated an 80% median reduction in long episodes with clean tolerability, confirming brain target engagement without widespread CNS depression.

**Why it could fail.** Psychiatric indications carry substantial placebo response rates; dampening localized neuro-excitability in seizures may not translate into statistically significant psychiatric mania score reductions.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=RAPP&ref=biostockinfo.com)

### PHAT — Phathom Pharmaceuticals, Inc.

CATALYST**fourth quarter of 2026**Data readout

RANK**77**

PRICE**$8.36**\-9% 20d

CAP**$676M**(81M sh)

CASH**$175M**\~57 mo

**Phathom expects topline results from the 12-week blinded portion of the Phase 2 pHalcon-EoE-201 trial of VOQUEZNA in eosinophilic esophagitis during the fourth quarter of 2026 (company's words; quarter-level precision).** The readout determines whether potassium-competitive acid blockade can achieve histologic remission and dysphagia relief.

**Company.** Phathom is a commercial-stage biopharmaceutical company marketing VOQUEZNA for gastrointestinal conditions including acid-related disorders. It generates commercial revenue from VOQUEZNA prescriptions, supported by an existing cash position and available credit lines to fund label expansions.

**Science & competition.** VOQUEZNA (vonoprazan) is an oral potassium-competitive acid blocker that inhibits gastric acid pumps to restore esophageal mucosal integrity. Rivals include Dupixent (Sanofi / Regeneron, FDA-approved (2022; expanded to ages 1–11 in 2024)) and Eohilia (Takeda, FDA-approved (2024)). Standard of care is dietary elimination therapy, high-dose proton pump inhibitors, or swallowed topical corticosteroids, with Dupixent reserved for refractory disease.

Competition sources

Sources: [regeneron.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEWFT-nx18AYVeLAPRwhT8RFidg4wkjq64fKm0DsJjP5vuGMVE4N7JixteEHUfwZz5qUvKN0pgc17sfk21o-30yUJ8fyPNeptkosniRQY3toDa73qG4BXoxLs9D%5FxrVfCLm-PJsRSCBAeiCHszYQaTISg4Rp934ZcWi9vCbRWJkQNCOX72ekKR6mCbd%5F%5FUO4uYpYQmcDu%5FgXjL4DjHAG5h506pdqNH-%5FJs62d5daapL0Sx-9J9wQOE=?ref=biostockinfo.com) · [cincinnatichildrens.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEYKW8qKOSLvyTzSHLa58dY-RdyY%5Fk6nT9qFI3EVyq87-3bIv5WufF90fy3NNP5fiGe9KQElMJGX6QymdGw5FAogCFiIiPblemOcl1LTlwmIm3HilVcjKCRoclNz4Cq0%5FWAg2i0Z9qK6CdXkPyDh463UbaKJ-J76GTHScVxnZdspZHIknkU1kG-kqBm1I1aaVrtd8Lz-mMS6p%5FafvEW2lo=?ref=biostockinfo.com) · [eosnetwork.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFNE18pTXRhvwFEWb17KxVM4xJ2W5V84Etl8DBE6VEAEF4X73hoLBO3Lp8Fky3vCbXV3sV3DhNKXsbabdEphALNttu66ZimUrlCo3gFrjvwvkULNVSjy7mbQd32SwXyDtOiUN%5FcDQKZBjspUXnFKHksDj-QkwF4ESaPEkB-nyqZLn4=?ref=biostockinfo.com) · [takeda.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQiZO15sOMsCuc2b3Bw-J3dlUCVEUWDb5ZHHraMsDLV5KqyZhEIhuut5HeV2LnIbLIPWslSkD7SA8s9Ltb7bb9T9XYcyJYlS0rOx6oxPWvn98-2FTWt4z6r-Bio3bBrViyrsupfOoad1o-Omtfy4GeaUnFbt7gTT44UC3QHE99Rmg=?ref=biostockinfo.com) · [prnewswire.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEk6UT-Pjk6Ipm34WJwgwGXPWbEPRD%5FNSsiu8Mftp2Y-aSKrMmH3WdVieVo-Zk-P6FFBTIh-xwTGDuwt6yjr%5FApcP4sT2xaaUn5g2dGmEPZv21qjdmvwuHq4GX-ifxRcFQ8m6Azgz0ZAjMcbWHW%5FVbEQnv86aqe1aPtpFlVHROljcOTAFf50SLEi8L0NvyitNXQNqKGo8OpH2Vpat35C22HBRiam20nv7xoiXOOEN-W%5F6%5FzVhfXB0GdREs2EB1fs3zDYWuKk0ccnry-wS9hMMAIerCP1RdmyPRJ-4JbBby6298fqoxag3n4Z7jRNd6CF-pJbVkd?ref=biostockinfo.com) · [astrazeneca-us.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHRgT6YxeCvEH1luNp9GTxm1JZbdQZd%5FbkOoXJmOkT782zwd5rNQwPNDmeAiuB5Pcjcq7BAmSJp9%5Faoyk72NIbRPMoHm7YMS9Keg%5FXq56N-lPp03-nG6XL4RWkithC5pUsWByfKVPwVzeZ9A7ZhpH20CC4dZQBBuyul9ihPMS0y%5FWDuMSC9lEMczW3uU89G5f4vwR%5F2NKHSxIcTCZ4c6Op3LzBnBP8=?ref=biostockinfo.com) · [eosnetwork.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFK-z0gDDz59Y-m6Bi7yKhy2ciOHtEiX3Ozy-2Ug1dIXozHsNiN4TRFqjqzjUkJeUqb8a1jyUpLaow3HhNyLYocA-mhNkaHXc%5F7cXqml%5Fd5NJsU0u9Mx3e5WJxPqSTb9ZBbNnIL2HGl2v2gUYz-sADvITSGFtwM8q11QopBUo6Ogq86PivYJvcw6r-0kgI2Es5ISFLTq-Dfoif40rkbqfuOVRpusCHDI6h3YO9siQ==?ref=biostockinfo.com) · [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHKfdOd-x5M-VUBi1kCjmKRvZzcVk1wZ0ez6xLViV3AA1RPYxTWpW9AJJ1wj8m-rcONxzB9WBbjZbWl33m2QtqtrSKwH3pEFOGamciIoSWvNFGQOjiGoW48qzfzuZL3jXypc9g=?ref=biostockinfo.com)

**Why it could work.** Vonoprazan produces faster and more durable acid suppression than conventional PPIs, potentially healing mucosal barrier disruption and halting eosinophil infiltration in patients with swallowing difficulties.

**Why it could fail.** Eosinophilic esophagitis is primarily an allergic type 2 immune disorder; acid suppression alone may fail to separate statistically from placebo on primary dysphagia symptom relief.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=PHAT&ref=biostockinfo.com)

### CLDX — Celldex Therapeutics

CATALYST**September/October 2026**Data readout

RANK**77**

PRICE**$36.90**\-13% 20d

CAP**$2.9B**(78M sh)

CASH**$669M**\~34 mo

**Celldex expects topline data from the Phase 3 EMBARQ-CSU 1 and 2 trials of barzolvolimab in chronic spontaneous urticaria in September/October 2026 (company's words; month-level precision).** The data decide whether targeted mast cell depletion delivers superior hive clearance over standard antihistamines and biologics.

**Company.** Celldex is a clinical-stage biopharmaceutical company focused on mast cell biology and inflammatory diseases. Its lead candidate barzolvolimab is in Phase 3 for urticaria and Phase 2 for atopic dermatitis. It has no approved products, relying on cash reserves.

**Science & competition.** Barzolvolimab is a monoclonal antibody that binds and inhibits the KIT receptor to deplete tissue mast cells driving allergic inflammation. Rivals include Omalizumab (Genentech / Novartis, Approved (2014; first biosimilar approved 2025)) and Dupilumab (Sanofi / Regeneron, Approved (April 2025 for ages ≥12; pediatric expansion to ages 2–11 approved April 2026)). Standard of care is stepwise management starting with second-generation H1-antihistamines titrated up to four-fold, followed by add-on targeted biologic therapy.

Competition sources

Sources: [healio.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHVHgLDJ4BAXZgjlV3B0-rFwvfEVOGlolAcv0uwB6MQFCvRKyM5MVcbkL%5FaMNmOm6C5cdQXhMvy3Pr-TPlfj12aEetm2tFCPB%5FOoEU%5FfpOCD2fuL4otz3701eoRFRmG0ZhD3L-AzimLF5xhP%5FG8-Du24WtHPlHZzQVfzZqwN57XPKVvxh1JPv0w3iyinQskDqruGggRvOKuvx6-USMqbrTIzQrqJTQiyHDh7sEY?ref=biostockinfo.com) · [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFjou05dutZkBe%5F4yPjg2jN75xbZvjd4XW0w2Z0FazJLKgFMKUQobZrBSwKiqw50et88RRNJMm5pZT7-B7AD%5FtfJ3FQkts0BxZ%5FFQuTicBIcym1X07%5FdgLAL6J9PpSb-NlFtao0Oli0XIU6bTY=?ref=biostockinfo.com) · [touchderma.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0W33Ec-3a8PV4j1sn1wiZOel3jyt106IHTaFE983gqor0b0gXsfW8cQeZxJJ7tqv3jnjZeTjfHp43fzGR92xvR8BGWOXv-EhqEaicV2QTmwMwytlg9XS7Vmz5oaEvLoIPRiIkY7nkqDUAE6s1bYB3orN9ULU%5FiusT2KRGRCq0D5jyYEMs5XKxreEVGpJXdgCPziKv9co6e1%5FnejVbD0k0Asc1TrruTIgy3KIQh7R4oIA8izeXZPQUVv1QMMfKJSMxjZQ2CqPetkXAYUtXNFpUnyI=?ref=biostockinfo.com) · [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG%5FiVXq49xWpUyhyJaeEGlr8ZsPlfNp11vuBHvqFPb2eYmSiYD4%5F0NiB2s6c0So1K5WMYvOdSQywaPiDIdFJolPARx1VhfEAiQlpnlM42QDYF2H5mS6XDEd9d2qmaI7OzsAYcKPA27XmugMXtRy?ref=biostockinfo.com) · [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFug7VHgSxyL2EIkKaYiAalxUspP0ulkz9Y1LbA-bODUAvvr5ypQutx7sI8hQsLKvCZT9OFFj3rtO74KEwYdMtRZQOTrb-HV2OopzjBaWwxuOxAAW3ynT8A-Ggvd-dLl6whWntr?ref=biostockinfo.com) · [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFaTijFQQaRfvWXgMyn1PTxRomUzyj3UIGwBQbxhBmmvF0K%5FT4lBNc8P-CH13k%5FX%5FHltYu%5FLpB-f6F0w0EeHUSOm99gJcpqvKvoVPA4XdXLSttJ5hkYxpVgAA-Aind4NB%5Ft4rk=?ref=biostockinfo.com) · [2minutemedicine.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFIRxi0ubgrkc-Khz8k5yYpJtqASmhe9Ap4NrgpOPhJx4rIh0-km9qbGu5MzaARULlv%5FvNOi-0izezDZpyzOVnWTmmINiLo477fWYU97ET-Bl1QNr5leao7ckU4H6UCUvqWbVmkebyy4qLYxV5byPrCES5kmxLDOt1etgqYLBAn6iCfBvtyrWQlAREHTag%5Fic%5FzeFM=?ref=biostockinfo.com) · [sanofi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE0ghD5LAbESSY8aGJ7r-6euK3EZfc3trKvw6Y%5FbZT9pm3WFlpwziJPVOkh%5FhduGvMQHKKgd4X3qk4ag5vKYKnARHRvCPNE0E4GpUCX5qlwBI9VpInMO8poRBEta7uiMv-XawgR3FaDysCfvxJK5r47uT3byHjJDV2V9-3Zzx-2pjqnbkhA0EKsZAQa7c-O?ref=biostockinfo.com)

**Why it could work.** In Phase 2, up to 64% of patients with baseline angioedema remained symptom-free at week 76 off-treatment, demonstrating deep, disease-modifying control through direct mast cell ablation.

**Why it could fail.** KIT inhibition carries on-target risks of hair hypopigmentation and neutropenia; severe hematologic toxicities or efficacy overlapping standard omalizumab would curtail commercial positioning.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=CLDX&ref=biostockinfo.com)

### BDTX — Black Diamond Therapeutics

CATALYST**fourth quarter of 2026**Data readout

RANK**76**

PRICE**$1.98**\-2% 20d

CAP**$114M**(58M sh)

CASH**$104M**\~38 mo

**Black Diamond plans to provide an update on the Phase 2 trial of silevertinib in frontline non-classical EGFR-mutant NSCLC in the fourth quarter of 2026 (company's words; quarter-level precision).** The update determines whether preliminary response durability and brain penetration hold as patient data mature.

**Company.** Black Diamond is a clinical-stage oncology company developing MasterKey small-molecule therapies for oncogenic mutations. Its lead candidate is silevertinib, evaluated in lung cancer and glioblastoma. The company generates no commercial product revenue, funding operations through existing capital and licensing receipts.

**Science & competition.** Silevertinib is an oral, brain-penetrant fourth-generation EGFR tyrosine kinase inhibitor targeting non-classical mutations. Rivals include Afatinib (Boehringer Ingelheim, FDA-approved (2018 label expansion specifically for uncommon/non-classical EGFR mutations: G719X, L861Q, S768I; initial )) and Amivantamab-vmjw (Johnson & Johnson, FDA-approved (2021 accelerated approval; expanded/full approval in 2024 with chemotherapy for exon 20 insertions)). Standard of care is afatinib alongside platinum-based doublet chemotherapy and off-label osimertinib per NCCN guidelines.

Competition sources

Sources: [onclive.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEYV7Akowf-rEb%5FL5Lu%5FNDMBZ7B1dnI7%5FdDqrt5IIa5ZsOmxPJOnfLtXFeQ%5F4yvXH%5FOknTCtBPaM4ZFCh6mlP4OeM3CpGgY%5F4ZJ13nA2djzjZuZ6nFec4oxG57LFOicwtQmi3vDciUbf3YaiVPH25UMlNqkq3zCFrHCrDKPvoNJba6K1j86-QOwdWgnJCNtC0gzs%5FhMW%5FcBggTJLnFRYFdpnwqSPDmfzEoZJPWHeJRqVrhoYVA=?ref=biostockinfo.com) · [onclive.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHSxw6lT7Fm8Gea5W90uDGiOta-QCO6AQoZyobcnQ1h4AxlIDxyMfXEyWn-79U3eBzWQTIbFVmtWEl8HXjMxjslut%5FffaZ5mS04RlAxgk-sq%5FQzM5HVtrKkjj-TtDY9BujwbgF-QmFMSon2P%5FPt4NakdJ2V6ihawrd-LKvTDAKQzI-JaJ3WzBsQF-bAa1gUb4nhLZJGqLhv%5FmmiED4Umns8ozpQ8HAzt9ZlKhCdaD9RcIduVmQ=?ref=biostockinfo.com) · [arrivent.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFPk9MnYqhp%5FujV7kfFxUVfNa7vCxB4zQSkbXK1ZsJzILPm8bARqY%5FHlYnEUwarzNzJvY9q2jUUXaVqsznh3I6aHbdQx2ZWwy%5FnYZIMxQOj6vG1yX1XI4N4KgxGr2kM0RXkINyLGsfCeVVXh6pPdGMWu-MRekG%5FrF9aeF0Upa509kCehOuPDa1OFfvnZsCvZv9mRoW0CUci-FNymj4V3M%5FhK71i3r-L97u42WEMnxSoVZNC?ref=biostockinfo.com) · [ascopubs.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFbx-%5Fk%5F%5FmnDNWr2lLc6XlsWP3rOiSO525AMeV1xrg5QNcEGBFG8fiKVm9fMFds8upV4e2LkaODlDqLpTromHmw2-5fgcqIXv02HYgyLy9LKf4hvFAl8K%5FT-0ZyTyZs1ZnOfbwYn1EbE55I?ref=biostockinfo.com) · [onclive.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHTpgEb70ZNupQfzflvLiTdVl-4MmoKyCoU4Co45RIh%5F3Pj4kRuqRpqlusayOtas0wIHnr7-Ze7iEidMtVGEDSoCbhPB28Y%5FGKYTOvLfXrqIZoxQ4BMYMK8zmMzssGG4cp89b0YNVp1khDDjLuRNfEA5zuTpA8M1aBp1jsrutvMLOIU01ub01jpZh1Jqc3zfw==?ref=biostockinfo.com) · [respiratory-therapy.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG5--4Mhp6tOzfvB%5FcJrqjT8Ku5ceJJynIZjCSrWWvMdE1sG0RGpkTSxRexZuiPO6HGqDQJBEK1O94waK0kYckGPwCMSrPnEAhp1zenLvC7yMFmU%5FMOFTxl8txexLmyoiTlNnFHomAryuC4-0VoQDA5Nm8Vpu2p1RGW3B6%5FrwosCnq07p5H4HcwHXu3d%5FGnWrGNNNVY7k8cJmWbZvnoEhbLdyBi8loawpsYizfdEVX4K8OHc1a%5Fpes7Symmr3s3Ws25GPV5-fVpUN3TlAxxmJldlnsr70nCOE6ZEcqHHr3WwwtNqHVLliYLcw==?ref=biostockinfo.com) · [lungcancerresearchfoundation.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQ9u2LMjVCZnWOGcVBSpdfdyoqa5Q4Ekat608DOVfCIpID2WNbgXaMnQy7iyNqqaftGBHrMNoMHVWIvALZNrBZW9aHxt3b-9DWpld6dIKbI2tvtbf9BNzQ6KI4mCBE6TPbzvdqNwZ8KOyLINaJZVLfcJmz9KEJ7KHTPqzLmjHlH8LriYIfpwXptNRRVSAF0Oht?ref=biostockinfo.com) · [squarespace.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEoNsdioSkrhkplnu4WGG%5FJ1VtP5ntmjLm8IgMcMDkSZa3Fk0LYAhNgPDjxTyGKd3P7kH3g10MwYEjG6m671u4wwAs-GlBaiB2rDl3Xt3Mta99yZKJ9a2PyGtvGvz2Je52FwLslDSmaZqf5O8%5FgEK1bXXbhvyswT9vfQFOuvI16DXKxUFHfwQ==?ref=biostockinfo.com)

**Why it could work.** Prior frontline Phase 2 data showed a 60% objective response rate, an 86% CNS response rate, and preliminary 15.2-month median progression-free survival across 35 non-classical variants.

**Why it could fail.** Median progression-free survival may contract below 12 months as patient follow-up lengthens, or the FDA could mandate an extensive randomized trial rather than an accelerated pathway.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=BDTX&ref=biostockinfo.com)

### ARVN — Arvinas, Inc.

CATALYST**Oct 4–Oct 8, 2026**Conference

RANK**76**

PRICE**$8.45**\-6% 20d

CAP**$552M**(65M sh)

CASH**$423M**\~25 mo

**Arvinas will present additional Phase 1 biomarker data for ARV-102 in Parkinson's disease at the International Congress on Parkinson's Disease and Movement Disorders between Oct 4–Oct 8, 2026.** The presentation decides whether targeted protein degraders can safely clear disease-driving kinase targets across the human blood-brain barrier.

**Company.** Arvinas is a clinical-stage biotechnology company developing targeted protein degraders for oncology and neuroscience. Its lead pipeline assets include ARV-102 alongside oncology candidates. It generates collaboration and milestone revenues, bolstered by recent out-licensing receipts from partners.

**Science & competition.** ARV-102 is an oral PROTAC designed to selectively degrade LRRK2, an enzyme whose hyperactivation drives neurodegeneration. Rivals include Vyalev (AbbVie, Approved: 2024) and Crexont (Amneal Pharmaceuticals, Approved: 2024). Standard of care is oral carbidopa/levodopa (dopamine precursor replacement) for symptomatic motor management in Parkinson's disease.

Competition sources

Sources: [alzforum.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHGc%5FYFF4BCdtatwjfsCbDIQz71S7br4qlwy5%5Fdf0tfUc06gfdMz1tF3UlXXWwedHMZSrWJkS4xRQ0mGKxWz5JgbdD2iz%5FMmiume5rOr8SWJEVurTKSzxqSr%5Fnh8K3DFF3LpfzJrXPcYA==?ref=biostockinfo.com) · [arvinas.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG3nsxVk6EIwPsqBpxWJFTqRk21FtYo6VA%5FcxOgU%5F%5Frz7P2blET9eOmH5c2zRdQ-g7Q0V5yXGc8yq2j5vhguJOzVevgdDG8Iz82dIFwGz8KuROUDkj6L4XF9Yj%5FhMwrl1kR5guu3SBIYzZem2pCln3anMJ6ncnheir4pHp5S5xc29%5FYFqew9-CNHsoP29sTH7xDHB6L1dX5r-ok-FmVmdw-uAofEfAcz5gENnzU2mDDBc2vlus=?ref=biostockinfo.com) · [biospace.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHnN6qeBPYGpuMdZJOC4aRytqNaA6kHWYdvUAgCx6TW0Hsmu61II%5FNz1ue18QjBYM2yojsgRJ3fsFpmSou%5Fp%5Ft04MaNYCRay6mQc%5F8i1%5FmiSubRQKQafiJHgkb5dQ1HfRuDs2zvFd%5FVlicG2mVMfxzBIdeZajKrKFLKPYymW8xItssRVKDV69SKILEvBJ6eOSmYxGOecpuqW5GtptCpaRSfJXHLAx9XYd99rW6NdxV7tKc=?ref=biostockinfo.com) · [parkinsons.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHuWjdZpFz%5F72SWsj55bP1F7a7py6kZ7nDg1-LYJQ09No4HEHv2fHgnDNM%5FQ%5FUiiK80E1EA7fvrLHgKLByzxcziNAmtdjOkJhkTflgzAtXhAbUZBK54lDCKmrg=?ref=biostockinfo.com) · [parkinsons.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFPQcnhABtpZrlwwPzC%5FlgVE4wTe2jB0TFqiz%5FL-atHPVfZUmOs1HapgY%5FrF0UzSdoMb0P-RsBHIUBvk%5FRQqGNha7npS6rvSZd7JDpJfGA5hJav1cm5DRyUkF3Z4aPD9ty9ZjCAez3dKYzA?ref=biostockinfo.com) · [neurodex.co](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGfY6oQjtM-mfozBfiW9v9ki%5FPzLhjANH7w5U1kJszg0NBWzegCqKl23s9S7GE589G%5FV-zgM%5FvtRU7KfwFpzxmuissLHc9O4RRlmczuuHe53A0w6dHPvSYZEt8UvgqsRFOK6xNUoO1NYPUBCna-uzs5FFYvbksK%5FfETng==?ref=biostockinfo.com) · [apdaparkinson.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFigg4ROH1tZlc0lVwgv1at%5FcCJ0YQcAJoRF04qbQBwbWguFeePvJ9So26WeAXmlxjac5l%5F9NmW%5FfEhM%5FxLqiRqEUZLShnpb3jSKr0HsAdxqHleeJ71ZLN68qUAenPqbgb7xy6VrIh4jC0k3ss-s6XxH8N67%5F305VCb62pnuOCkVRFC4C2UDRoaBII=?ref=biostockinfo.com) · [cerevance.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEt8Y7CNFsFig38XRcJEJt%5FC5iGyloTerGSc8PHEQEOFDtdz36ESxcAHpBkdtkMI5hYjNh790RF5sFB5tS8KT0rpZp9-qKpYiZhJaUtc6NTZ%5FiJGYag79iFu3zNBQ8fPawKH52tnnMSecWC2PYF5Yfi-lW10cNjUNTSRrLiL8LXBRKnDROL9nCgMHyrk9jryiFIYB1ZfcuAtrcm9IeGZdVlVW1Az6QuAzCVA6dWANkoWlTjQvG7jvBMeLzFibooTW6D1JlF6cSlsi6akHMKUuEVEziCkhSZfUr6hHWq-7UySipcO1X3oUKtt7Vc0k-HOw==?ref=biostockinfo.com)

**Why it could work.** Initial Phase 1 findings presented at AD/PD 2026 demonstrated greater than 50% LRRK2 degradation in cerebrospinal fluid, confirming meaningful central target degradation in humans.

**Why it could fail.** Preclinical LRRK2 inhibition has shown structural liabilities in lung and kidney tissues; inconsistent central biomarker reduction or emergent peripheral organ toxicities would halt clinical progression.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=ARVN&ref=biostockinfo.com)

### MRK — Merck & Co., Inc.

CATALYST**Oct 4, 2026**Regulatory

RANK**75**

PRICE**$143.93**+6% 20d

CAP**$355.1B**(2,467M sh)

CASH**$6.8B**no net burn

Priority Review Filing warning

**The FDA has set a PDUFA target action date of October 4, 2026 for WELIREG plus Lenvima in previously treated advanced renal cell carcinoma. Priority Review.** The regulatory decision decides whether belzutifan expands into second-line clear cell combinations based on Phase 3 LITESPARK-011 results.

**Company.** Merck is a global healthcare company marketing prescription pharmaceuticals, vaccines, and oncology therapies led by KEYTRUDA. It generates dozens of billions in commercial revenue annually, maintaining positive operating cash flow while managing portfolio transitions.

**Science & competition.** WELIREG (belzutifan) is an oral hypoxia-inducible factor-2 alpha inhibitor that blocks oncogenic transcription driven by VHL mutations in renal clear cells. Rivals include Cabometyx (Exelixis, FDA-approved) and Fotivda (AVEO Oncology (LG Chem), FDA-approved). Standard of care is first-line ICI dual therapy or ICI plus VEGF-TKI combinations, with subsequent lines using alternative VEGFR-TKIs, lenvatinib plus everolimus, or belzutifan.

Competition sources

Sources: [cancernetwork.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE3xZvVRa295ksIF7Lx5bURYwYM5oxMGFiie3iZHxTHTuw7razq7SwgkZdTYv9Fl1UMTRzP4zT7BnKW4WD835WoOlz5S-tMM5luZoKVSMPYojqvMcwjEuwz3aE5sy41B21x3Q844LOltE7%5FZHPzJ2ikqsRrA8yBMb9WEfNLtKU6Ru%5FwHEkTKBMLppXLSKBcgfUXI2HAMSxMBBwgCeqr%5F7%5FCC02vEprO?ref=biostockinfo.com) · [merck.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHrhmCOuNezcOJZuAtrGSbgiYUvLmHyQLBDSa5PXJe6bmVqhiQ7MaKfmvEsnZ0SPTIpTaP-KBriNsLg0MyrpVb93bH9znmwq2W%5F%5FsfpwuYPw0CVXvuISmziN1suRZ%5FynfQAmMDYGn3n1%5Fs8LWynU33YwhdlxyKme8s5Pz2Dl7ewD2%5F2ji-nN-sqrx1KiM8WvOgfSURnegY77tLP2EEl3M219EYJt51E2-osIY3zNvFOOl8kKlDpHqdMCcvzUw%5F-K2DoN-fcwmUk9zVuUOLzL%5Fkdf7DPjCCX9RGO9pVyl7eOzIOZhikHDaHkH2BDe52S8GFX3IVg2V7%5F3chWyJYQ%5FMF0uytR-ZZ8rwBMS7laCvOQ?ref=biostockinfo.com) · [targetedonc.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGO2KOYlQIfNGHIO%5FiPWn4ubDjLxTPlvCSndfNonE%5F4j0yg-7GI7fednurjc9sZ%5FInfN4H5%5FbhZcnS939SadLuGbvlnDujgu89YygOUz2Vr6Qnml052ZD-5cUiE2Xw-THzm7sdWLBsuXJ0j4bLvnSJlvG74t6dQN3sIIeQWqmOUKhiyePf31fkZNHYpcOiM6cHOYyb7?ref=biostockinfo.com) · [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFM3GC5jLV7xGfigwyEpae%5FJwiRqdZT%5FxBhR1De4jkPB%5FZBF6BOngPm63pEBMPG7OexOyPcsAP622ofDyzQ3r7DckDrO4V%5FpHb8HLmUbUuKwAnwN0B6PKC8k4HOJDtiqVa5ojn8DPFKs0E-EZs=?ref=biostockinfo.com) · [medpagetoday.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGY6Car9pDEPVtpv2A8xxDfeXe0xECztO0jvX4j1k6yn5c8JLsZQIw3KXtcZwt6NdrqIwXH3MT2TyG5s3w4DeyeTObeTIGQq2E5e2jxlBkackHCbfGClkZNT7Dv7l-NbEjUtK0x5CNITvF4MGGA7-tqXQU=?ref=biostockinfo.com) · [urologytimes.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGp65JFWRF4a-r8kIJj7KWMTzstcd4bbDFfTBYJukC8ODR9s016YeVTClQ6sy%5Fd659ZifNgJGRZ-WENdY3IqMfnj6SA2v1LVq51U3hG%5FOtToDOACy8qG9PawL0Nhj4tpi0DL8usFi8k0EHvKsu-vErZ6LEnf6CKa9wBAugE0fQXYhHqqQEmZbJNFqKzxzA4FeOtlz8vHJ5oGUVZ4Ro3xwn5mSebhMNo1Kk9v0w=?ref=biostockinfo.com) · [urotoday.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFvgoeTFMqpBFkiXcqqVAPdOVa-nknoGEy7cVfDf%5FbG4qCT%5Fk7CAHvbt2uVj1yE96hc4QYNG%5FziZDt9dsTvmVqbkdMnCNxkimeQoFkJl4lp4MPQHOzSQxh93gFQhqKBtUfpnKhY-oV1GFdCP0xt9xJSrNncnTO-7Sk2Fh6xXqbL2uZItRlBc45mrLmDnEdDnfZMT6RYf7q65oTEZ9pTm5J%5FEIfazvebYhYrxeaLAvZ8UzQWg4kEiAKBO4hb-q89AWOP7lYYN6HGIvz0Ds7uBnv73Rv8KQWkr5fAGIhBn4-MahB7PFcFy-kbvjOoRbhL9pMaNtXtYQfRJPNP5lEql0NZc4g2kBvy2h7tUAEu1-1633FrNvQyyeJYGFYggwEDSd71yiT8-fmf-j8VCcyiE1uj3%5FEwLBwrUZxGdVMZanWlnpJ4RIbU3TP2ofSmqJubjCB127s=?ref=biostockinfo.com) · [arcusbio.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFJVsFytxTOB2hPvT-2RkeKACVuHBcKK1vAPQix%5F4lkRMP%5FmZGKkCz-G8A3gs7Yojc%5FyOEHHgjrlkVtDhaJD7nKsbmeUxgz5g3t3EitPuRzu4uijdhV3kppN8QJiC-lK10pAC2r%5Fig=?ref=biostockinfo.com)

**Why it could work.** Phase 3 LITESPARK-011 demonstrated that adding WELIREG to Lenvima reduced the risk of disease progression or death by 30% compared to cabozantinib in previously treated renal cell carcinoma.

**Why it could fail.** On-target hypoxia and severe anemia can compound TKI toxicities, which could lead regulators to restrict labeling or demand heavy warning language that hinders clinical adoption.

**Recent development.** On August 19, [Merck and Moderna reported](https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/?ref=biostockinfo.com) positive Phase 3 melanoma results for intismeran plus KEYTRUDA. This provides a separate oncology pipeline update alongside the upcoming WELIREG decision.

**Filing flag.** GAAP net loss attributable to the company was $1,335 million in Q2 2026 and $4,240 million in Q1 2026, driven significantly by acquisition-related charges including Terns and Cidara.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=MRK&ref=biostockinfo.com)

## Watchlist

### BFRI — Biofrontera Inc.

CATALYST**Sep 28, 2026**Regulatory

RANK**74**

PRICE**$1.55**+23% 20d

CAP**$23M**(15M sh)

Cash $0M, \~0 mo

Going-concern warning

The FDA has set an sNDA PDUFA target action date of September 28, 2026 for Ameluz photodynamic therapy in superficial basal cell carcinoma. In completed trials, Ameluz achieved a 58% inflammatory lesion reduction in acne vulgaris and met Phase 3 endpoints for actinic keratosis. Management states that existing conditions raise substantial doubt about the company's ability to continue as a going concern, exacerbated by an International Trade Commission exclusion order.

**Filing flag.** Management states that conditions raise substantial doubt about the Company's ability to continue as a going concern for at least twelve months from the issuance date of the August 13, 2026 Form 10-Q. An International Trade Commission exclusion order related to the RhodoLED XL lamp took effect on July 7, 2026.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=BFRI&ref=biostockinfo.com)

### CLLS — Cellectis

CATALYST**Q4 2026**Data readout

RANK**74**

PRICE**$3.10**\-3% 20d

CAP**$225M**(73M sh)

Cash $158M, \~46 mo

Cellectis expects its first interim analysis for the pivotal Phase 2 BALLI-01 trial of lasme-cel in relapsed/refractory B-ALL in Q4 2026 (company's words; quarter-level precision). In Phase 1 target cohorts, lasme-cel demonstrated a 100% overall response rate and 57% complete remission with incomplete count recovery, with 75% achieving MRD negativity. With $169 million in cash and term deposits, cash runway extends into Q4 2027.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=CLLS&ref=biostockinfo.com)

### CMPX — Compass Therapeutics, Inc.

CATALYST**Oct 23–Oct 27, 2026**Conference

RANK**74**

PRICE**$2.00**\-12% 20d

CAP**$360M**(180M sh)

Cash $168M, \~36 mo

ODD

Compass Therapeutics will deliver an oral presentation of Phase 2/3 COMPANION-002 data for tovecimig in biliary tract cancer at the ESMO Congress between Oct 23–Oct 27, 2026\. The combination improved overall response rate to 18.0% versus 5.3% for paclitaxel alone and significantly prolonged progression-free survival to 4.7 months compared to 2.6 months. The company expects FDA regulatory feedback this quarter ahead of a planned BLA filing, supported by cash into 2028.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=CMPX&ref=biostockinfo.com)

### ANNX — Annexon, Inc.

CATALYST**fourth quarter of 2026**Data readout

RANK**74**

PRICE**$3.94**\-25% 20d

CAP**$747M**(190M sh)

Cash unavailable

PRIME FTD

Annexon expects Month 15 primary endpoint data from the Phase 3 ARCHER II trial of vonaprument in geographic atrophy in the fourth quarter of 2026 (company's words; quarter-level precision). The 659-patient trial evaluates visual protection, supported by recent open-label FORWARD data in Guillain-Barré syndrome showing early functional gains. Cash and a newly executed credit facility provide financial runway into 2028.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=ANNX&ref=biostockinfo.com)

### DMAC — DiaMedica Therapeutics

CATALYST**September**Data readout

RANK**73**

PRICE**$6.47**\-4% 20d

CAP**$349M**(54M sh)

Cash $37M, \~14 mo

DiaMedica will report topline results and hold a key opinion leader call for its Phase 2 early-onset fetal growth restriction cohort of rinvecalinase alfa in September (company's words; month-level precision). Prior Phase 2 late-onset preeclampsia data demonstrated mean acute blood pressure reductions of 29.1 mmHg systolic and 17.0 mmHg diastolic. The company maintains an active ATM program and reported $43.5 million in cash providing runway for 12 months.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=DMAC&ref=biostockinfo.com)

### FTH — Faeth Therapeutics

CATALYST**year-end 2026**Data readout

RANK**73**

PRICE**$37.44**+31% 20d

CAP**$968M**(26M sh)

Cash $179M, \~64 mo

Faeth Therapeutics expects Phase 2 topline data for PIKTOR in second-line advanced endometrial cancer by year-end 2026 (company's words; quarter-level precision). The trial evaluates multi-node PI3K/AKT/mTOR pathway inhibition, with concurrent Phase 1b/2 development underway in advanced breast cancer. The company holds $186.4 million in cash following a $200 million financing, sufficient to fund operations through both planned clinical readouts.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=FTH&ref=biostockinfo.com)

### PALI — Palisade Bio

CATALYST**Oct 9–Oct 14, 2026**Conference

RANK**73**

PRICE**$2.06**\-4% 20d

CAP**$359M**(174M sh)

Cash $121M, \~80 mo

Palisade Bio will present clinical data for its oral PDE4 inhibitor PALI-2108 at the ACG Annual Scientific Meeting between Oct 9–Oct 14, 2026\. Prior Phase 1 trials demonstrated clinical responses in all 5 ulcerative colitis patients and an endoscopic response in 2 of 5 fibrostenotic Crohn's disease patients. Cash of $125.2 million provides runway into 2028, funding Phase 2 initiation in the second half of 2026.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=PALI&ref=biostockinfo.com)

### OCS — Oculis Holding AG

CATALYST**around year-end**Data readout

RANK**72**

PRICE**$10.56**\-18% 20d

CAP**$717M**(68M sh)

Cash $47M, \~8 mo

Oculis expects topline data from the PREDICT-1 registrational trial of licaminlimab in dry eye disease around year-end (company's words; quarter-level precision). The trial evaluates a precision genotype-targeted approach, following positive Phase 3 DIAMOND results in diabetic macular edema and Phase 2 data in optic neuritis. Management reports $215.3 million in liquid assets funding operations into 2029.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=OCS&ref=biostockinfo.com)

### IVA — Inventiva

CATALYST**the fourth quarter of 2026**Data readout

RANK**72**

PRICE**$4.02**\-13% 20d

CAP**$777M**(193M sh)

Cash $274M (burn n/a)

financing filed since the cash dateBTD FTD

Inventiva expects topline results from the Phase 3 NATiV3 trial evaluating lanifibranor in non-cirrhotic MASH in the fourth quarter of 2026 (company's words; quarter-level precision). The 1,009-patient trial assesses histological MASH resolution and fibrosis improvement after 72 weeks of daily oral dosing. Liquid assets of €233.9 million are projected to finance planned corporate operations into the first quarter of 2028.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=IVA&ref=biostockinfo.com)

### EPRX — Eupraxia Pharmaceuticals Inc.

CATALYST**in Q4 2026**Data readout

RANK**72**

PRICE**$8.42**+26% 20d

CAP**$551M**(66M sh)

Cash $126M, \~40 mo

Eupraxia expects Phase 2b interim data from the randomized, placebo-controlled RESOLVE trial evaluating EP-104GI in eosinophilic esophagitis in Q4 2026 (company's words; quarter-level precision). Phase 1b/2a cohorts demonstrated substantial long-term reductions in severe dysphagia with zero reported treatment-emergent serious adverse events. Liquid assets of $133.7 million provide over three years of operating runway.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=EPRX&ref=biostockinfo.com)

## The Take

This week's scanner reflects a bifurcated slate of late-stage readouts where macro headwinds demand clinical differentiation. With ten-year Treasury yields hovering at 4.97% and small-cap breadth depressed at 33%, the market offers zero leeway for incremental data. Commercial-stage label expansions such as AKBA and PHAT offer defensive margin safety, as both firms generate revenue while attempting to replace injectable biologics with oral therapies. In contrast, pure-play binary readouts like CLDX in urticaria and IRD in presbyopia face sharp valuation adjustments where success unlocks registrational filings while equivocal data punishes rich multiples. Meanwhile, platform names like RAPP and ARVN carry downside cushions because their lead valuations remain anchored in separate indications, leaving their upcoming manic and neurodegenerative readouts as unpriced call options.

*How the scanner ranks names, estimates cash and reads dates is explained in [the methodology note](https://www.biostockinfo.com/methodology/). Companies' own words and SEC filings are the only source for every date above; rivals are named from a cited web search. Not investment advice.*

## Supported by readers

Any amount of support helps improve the calendar and maintain the catalyst newsletter.

[One-time support · choose any amount →](https://buy.stripe.com/dRm6oA6ztcFldWQ935cwg00?ref=biostockinfo.com)

## Disclaimer

For information and education only; not investment advice or a recommendation to buy or sell any security. This AI-assisted newsletter may contain errors or omissions, and catalyst dates can change. Verify details against original sources and do your own research. Biotechnology investing involves substantial risk, including loss of capital.